跳至主要内容
临床试验/EUCTR2007-000805-32-GB
EUCTR2007-000805-32-GB进行中(未招募)1 期

AN INVESTIGATION INTO THE ROLE OF PARACETAMOL (ACETAMINOPHEN) AT STEP 3 OF THE WHO ANALGESIC LADDER

The Royal Marsden NHS Foundation Trust0 个研究点目标入组 80 人开始时间: 2007年3月9日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
80

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

入选标准

  • 1.Clinical diagnosis of cancer.
  • 2.Age =18yr.
  • 3.Taking regular opioids for moderate to severe pain (i.e. 4hrly normal release opioid; 12hourly modified release opioid; or a transdermal patch - step 3 of the WHO analgesic ladder) for the preceding 7 days.
  • 4.Taking = 2g / day paracetamol for the preceding 7 days.
  • 5.Average pain score for the preceding 24hrs =4 on a 0-10 numerical rating scale (NRS).
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • 1.Unwilling to stop paracetamol
  • 2.No diagnosis of malignant disease.
  • 3.Age <18yr.
  • 4.Prognosis <2weeks.
  • 5.Radiotherapy treatment in the preceding 4 weeks.
  • 6.New anti-cancer treatment in the preceding 4 weeks.
  • 7.Average pain score for the preceding 24hrs =5 on NRS.
  • 8.Significant cognitive impairment, i.e. unable to complete pain questionnaire.

研究者

相似试验